HebeCell and Logomix form a strategic partnership to develop gene-edited NK cells and genetic modifications to create next gen designer NK cells.
HebeCell Corp (“HebeCell”) today announced that it has successfully closed a US$53 million Series A financing to advance its unique off-the-shelf pluripotent stem cell (PSC)-CAR-NK products into clinics. This strategic investment is led by Jacobio Pharmaceuticals (“Jacobio” 1167.HK), who will collaborate with HebeCell to develop the next-generation PSC-CAR-NK therapy for cancer, viral infection, and autoimmune diseases.
Proteintech and HebeCell announce their collaborative partnership to develop proprietary nanobody based chimeric antigen receptor (nCAR) technology for the development and commercialization of iPSC-derived natural killer (iPSC-nCAR-NK) cells, a promising cellular immunotherapy treatment for cancer and other diseases.
Ankarys Therapeutics Inc. (Ankarys), Applied StemCell, Inc. (ASC), and HebeCell Corp. (HebeCell) announced that they have entered into a strategic collaboration to co-develop allogeneic induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR) NK cell therapeutics targeting hematological malignancies.